Private CNS Company Review 2012 Released by NI Research

News provided by

Mar 08, 2012, 08:20 ET

CARDIFF, Calif., March 8, 2012 /PRNewswire/ -- NI Research, the publisher of independent and authoritative reviews of the neurotherapeutics area, has released the 2012 edition of the Private CNS Company Review. PCNS provides a unique database of information about the private companies specializing in the development of novel therapeutics for neurological/psychiatric disorders. PCNS describes and appraises scientific platforms; clinical/preclinical activity; contact information; alliances; financing; prospects, and licensing opportunities.

"In an era where many major pharmaceutical companies are still trying to develop a coherent and effective strategy for neuroscience, much of the most creative and promising R&D for neurotherapeutics is being carried out by privately held companies. The 138 companies reviewed in PCNS cover the full gamut of innovation, from those addressing highly innovative albeit risky novel targets, to companies developing clinical-stage modifications of familiar mechanistic themes," notes Harry Tracy, PhD, President of NI Research (http://www.niresearch.com).

"Not all of them are going to be productive; there is both excellence and mediocrity to be found in this group, but any large or midsize pharmaceutical company intending to participate in the next generation of neurotherapeutics must pay close attention to the programs in development by these firms. No other publication focuses on this area with the depth and comprehensiveness of PCNS; it is a unique resource for Business Development teams at companies of any size," said Tracy, who provides consultation services to the neuropharm industry.

The Table of Contents for the 2012 edition of the Private CNS Company Review:

Private CNS Company Fates/Casualties

Private CNS Company Destinations

Private CNS Company Funding 2011

Opportunities by Stage of Development

2012 PCNS Inflection Points

Top Five PCNS Partnering Opportunities

Four PCNS Subsets: Neurotrophic Factors, Novel Pain Mechanisms, Novel Antidepressants, Novel Schizophrenia Drug Mechanisms

Company Reviews:

Accera

AC Immune

Acumen Pharmaceuticals

Adamas Pharmaceuticals

Aestus Therapeutics

Affectis Pharmaceuticals

Afferent Pharmaceuticals

Affiris

Afraxis

AgeneBio

American Life Science Pharmaceuticals

Archer Pharmaceuticals

Arcion Therapeutics

Ariel Pharmaceuticals

ArmaGen Technologies

Astraea Therapeutics

AurimMed Pharma

AviNeuro

Avraham Pharmaceuticals

Axerion Therapeutics

Axon-Neuroscience

Azevan Pharmaceuticals

Bayhill Therapeutics

BioArctic Neuroscience

BioAxone BioSciences

BioChromix Pharma

Biocrea

BrainCells

BrainTact

Cambria Pharmaceuticals

Canbex Therapeutics

Cara Therapeutics

CeNeRx BioPharma

Cerecor

Ceregene

Chaperone Therapeutics

Clera

Cognition Therapeutics

Cognosci

Collegium Pharmaceuticals

CoLucid

CoMentis

Convergence Pharmaceuticals

Cortica Neuroscience

Cyrenaic Pharmaceuticals

Dart Neuroscience/Helicon Therapeutics

Domain Therapeutics

Embera Neurotherapeutics

ENKAM Pharmaceuticals

EnVivo Pharmaceuticals

Envoy Therapeutics

Euthymics Bioscience

Galantos Pharma

Galenea

GeNeuro

Hermo Pharma

Insero Health

Intra-Cellular Therapies

Karuna Pharmaceuticals

KeyNeurotek

Knopp Biosciences

Kyalin Biosciences

Maas Biolab

Mapreg

Marinus Pharmaceuticals

Medeia Therapeutics

MedGenesis Therapeutix

MediProPharma

Mind-NRG

Mithridion

Mnemosyne

M's Science

MSI Methylation Sciences

Naurex

Nautilus Neurosciences

Neuraltus

NeurAxon

Neurim

Neurimmune Therapeutics

NeuroGeneration

Neurogenetic Pharmaceuticals

NeuroHealing

NeuroKin

NeuroKos

Neurolixis

Neurona Therapeutics

Neuronascent

NeuroNova

NeuroP

NeuroPhage

NeuroPore Therapies

Neurotez

NeuroTherapeutics Pharma

Neurotune

New World Laboratories

NoNO Inc.

Noscira

NsGene

Oligomerix

Pharmacofore

PharmaNeuroBoost

PharmatrophiX

Pharmaxon

Pharnext

Prexa Pharmaceuticals

Probiodrug

ProMentis Pharmaceuticals

Proneuron Biotechnologies

Proteostasis Therapeutics

Psyadon Pharmaceuticals

Q Therapeutics

QR Pharma

Receptos

Regenesance

Remedy Pharmaceuticals

ReMYND

ReXceptor

Sage Therapeutics

SanBio

Satori Pharmaceuticals

SCT Spinal Cord Therapeutics

Seaside Therapeutics

Senexis

SenexTa Therapeutics

Sinapis Pharma

SMART Biosciences

Somnus Therapeutics

Sonexa Therapeutics

Spinifex Pharmaceuticals

Synchroneuron

TauRx

TauTaTis

TheraQuest Biosciences

to-BBB

Trigemina

Trophos

Xenome Ltd

Zenobia

On the Cusp ...

Programs by Company, Indication, Stage

Company Funding

VC CNS Portfolios

Private CNS Company Review 2012 is the annual, independent review of the private neuroscience company universe. The cost of PCNS 2012 is $4,000 for NeuroPerspective subscribers, $5,000 for nonsubscribers. Startup companies can contact us for pricing options.

About NI Research

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.

For information, go to http://www.niresearch.com

Blog: http://neurogram.wordpress.com

SOURCE NI Research